Torrent Pharma reports strong Q3 earnings and JB Pharma acquisition
pre-market1 source ↓written by the desknot a recommendation
- in Q3 FY26
- 17.6% YoY increase
- Nine-month revenue reached
- ₹9,783 cr
Torrent Pharmaceuticals reported consolidated revenue of ₹3,303 cr, a 17.6% YoY increase in Q3 FY26, driven by strategic growth initiatives including the JB Pharma acquisition. Net profit surged 26.2% YoY to ₹635 cr, reflecting robust operational performance. This strong financial performance may enhance investor sentiment in the pharma sector.
• Operating EBITDA rose 19% YoY to ₹1,088 cr
• EBITDA margin stable at 33%
• Nine-month revenue reached ₹9,783 cr, up 14.2% YoY.
Not investment advice. For informational purposes only.